Development of a risk scoring system for evaluating the prognosis of patients with Her2-positive breast cancer

BACKGROUND: As one of the many breast cancer subtypes, human epidermal growth factor receptor 2 (Her2)-positive breast cancer has higher invasiveness and poor prognosis, although the advent of anti-Her2 drugs has brought good news to patients. However, the emergence of drug resistance still limits i...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Chundi, Zhuang, Jing, Li, Huayao, Liu, Cun, Zhou, Chao, Liu, Lijuan, Feng, Fubin, Sun, Changgang, Wu, Jibiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Primary Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7161270/
https://www.ncbi.nlm.nih.gov/pubmed/32322168
http://dx.doi.org/10.1186/s12935-020-01175-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7161270/
https://www.ncbi.nlm.nih.gov/pubmed/32322168
http://dx.doi.org/10.1186/s12935-020-01175-1

Ejemplares similares